Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Orphan Indications Pipeline Insights, 2015 - A DelveInsight’s ReportDelveInsight, the leading market research and consulting company serve as a Knowledge partner across the value chain of Pharmaceutical Industry. We made strong presence in Orphan market with 200+ Reports on Orphan based indications Pipeline Insights.
By: DelveInsight Business Research Products intended to treat rare diseases are developed to treat patients suffering from very serious diseases for which no treatment, or at least a satisfactory one, has so far been available. The number of rare diseases for which no treatment is currently available is estimated to be between 4,000 and 5,000 worldwide. The current economic situation plus the huge generic competition shifted the focus of pharmaceutical companies from the essential medicines to the new business model such as orphan drugs. The new business model of orphan drugs could offer an integrated healthcare solution that enables Pharma companies to develop newer areas of therapeutics, diagnosis, treatment, monitoring, and patient support. DelveInsight’ DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email at info@delveInsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|